Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer
NCT03939481 · View on ClinicalTrials.gov ↗
Study Summary
This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk factors, such as age, gender, pre-existing conditions, and the type of treatment for cancer may help doctors estimate how likely patients are to develop the nerve disorder.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Functional Assessment
- DRUG Chemotherapy
Study Locations (20)
California
- Kaiser Permanente-Deer Valley Medical Center — Antioch
- Kaiser Permanente Dublin — Dublin
- Kaiser Permanente-Fremont — Fremont
- Kaiser Permanente-Fresno — Fresno
- Kaiser Permanente-Oakland — Oakland
- Desert Regional Medical Center — Palm Springs
- Kaiser Permanente-San Francisco — San Francisco
- Kaiser Permanente-Santa Teresa-San Jose — San Jose
- Kaiser Permanente San Leandro — San Leandro
- Kaiser San Rafael-Gallinas — San Rafael
- Kaiser Permanente Medical Center - Santa Clara — Santa Clara
- Kaiser Permanente-Santa Rosa — Santa Rosa
- Kaiser Permanente Medical Center-Vacaville — Vacaville
- Kaiser Permanente-Vallejo — Vallejo
- Kaiser Permanente-Walnut Creek — Walnut Creek
Delaware
- Bayhealth Hospital Kent Campus — Dover
- Bayhealth Hospital Sussex Campus — Milford
Florida
- Florida Gynecologic Oncology — Fort Myers
- Regional Cancer Center-Lee Memorial Health System — Fort Myers
Colorado
- Rocky Mountain Regional VA Medical Center — Aurora
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,336 participants |
| Start Date | 2019-05-14 |
| Est. Completion | 2026-02-28 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03939481
The ClinicalTrials.gov registry entry for NCT03939481 describes a study currently listed as active not recruiting. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,336 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 212 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 10 conditions, with Anatomic Stage III Breast Cancer AJCC v8 appearing as the primary indexed condition, and to 3 interventions — of which Questionnaire Administration is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03939481 reports 20 study locations spanning 4 distinct geographic areas — top geographies include California, Delaware, Florida. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03939481 about?
NCT03939481 is a clinical study titled "Treatment Effects on Development of Chemotherapy-Induced Peripheral Neuropathy in Patients With Cancer". This trial studies treatment effects on development of chemotherapy-induced peripheral neuropathy in patients with cancer. Treatments for cancer can cause a problem to the nervous system (called peripheral neuropathy) that can lead to tingling or less feeling in hands and feet. Studying certain risk...
What is the current status of trial NCT03939481?
This trial is currently active not recruiting. The enrollment target is 1,336 participants. The study started on 2019-05-14. Estimated completion is 2026-02-28.
What conditions does trial NCT03939481 study?
This clinical trial studies the following conditions: Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03939481?
The interventions under investigation include: Questionnaire Administration (OTHER), Functional Assessment (OTHER), Chemotherapy (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03939481?
This trial is sponsored by SWOG Cancer Research Network, which has 212 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03939481 being conducted?
This trial has 20 study locations across California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.